News >

Sharma Stresses Importance of Refining Immunotherapy in GU Cancers

Brandon Scalea
Published: Monday, Sep 10, 2018

Dr Padmanee Sharma

Padmanee Sharma, MD, PhD
Immunotherapy has demonstrated encouraging data in some genitourinary (GU) cancers, but there is still much work left to make it a “pillar” of cancer treatment in this space, said Padmanee Sharma, MD, PhD.

Sharma shared insight on the current state of immunotherapy in the treatment of patients with GU cancers.

OncLive: What is the state of immunotherapy in GU cancers?

Sharma: [Immunotherapy] should be one of the major arms of treatment that you can use. The next step is how to make it better. Immunotherapy has been FDA approved for other tumor types like melanoma, head and neck cancer, lung cancer, bladder cancer, and kidney cancer. We need it to work in multiple tumor types in terms of GU cancers. Right now, it's not working in prostate cancer, pancreatic cancer, ovarian cancer, and some others.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x